Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

LENVIMA

LENVATINIB MESYLATE

Standard Dose
EQ 4MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview LENVIMA is listed in Drugs@FDA under application 206947 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient LENVATINIB MESYLATE Form and strength CAPSULE;ORAL - EQ 4MG BASE Sponsor EISAI INC Submission history Latest submission status date: 2025-01-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview LENVIMA is listed in Drugs@FDA under application 206947 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient LENVATINIB MESYLATE Form and strength CAPSULE;ORAL - EQ 4MG BASE Sponsor EISAI INC Submission history Latest submission status date: 2025-01-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.